Appropriate administration schedule of D-penicillamine for pediatric Wilson's disease patients based on urinary copper excretion

被引:2
|
作者
Fukuoka, N [1 ]
Morita, S
Hamatani, S
Okada, H
Kondoh, M
Imai, T
Ohnishi, S
Itoh, S
机构
[1] Kagawa Med Univ, Dept Hosp Pharm, Kagawa, Japan
[2] Kagawa Med Univ, Dept Pediat, Kagawa, Japan
关键词
Wilson's disease; D-penicillamine; urinary copper excretion; administration schedule;
D O I
10.1248/yakushi.122.585
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The purpose of this study was to increase the amount of copper excreted resulting from the administration of D-penicillamine (DP) in pediatric Wilson's disease (WD) patients. By measuring the urinary copper excretion after adjusting the administration schedules, the appropriate timing for DP administration was investigated. The subjects were three brothers with pediatric WD. The initial daily dose of DP was 5 mg/kg/day, and gradually increased to the maintenance dose of 20 mg/kg/day. Until the maintenance daily dose was reached, DP was administered 2 h after the morning and evening meal. After reaching the maintenance daily dose of DP, the appropriate timing for taking DP was investigated in both the morning and evening. Three schedules of DP administration were compared: 2 h after meals; 30 min before meals (with fasting); and 1 h before the morning and 1.5 before the evening meal (direction 1). The resulting urinary copper excretion on each dosing schedule was compared. Little difference was found in urinary copper excretion on the first two schedules, i.e., 2 h after meals and 30 min before meals. When DP was administered 30 min before meals, urinary copper excretion [mug/day] was 1173 in the first brother, 918 in the second, and 875 in the third. When DP was administered according to direction 1, however, urinary copper excretion was increased significantly to 1701 in the first brother, 2701 in the second, and 3808 in the third. It is known that the efficiency of urinary copper excretion with DP administration depends on the maintenance of chelating ability after absorption from the gastrointestinal tract. Our results indicate that the excretion was lower when DP was administered 2 h after or 30 min before meals (with fasting), as recommended in the package insert. Thus to achieve better copper excretion efficiency, direction 1 is recommended for WD patients.
引用
收藏
页码:585 / 588
页数:4
相关论文
共 50 条
  • [21] Metal Element Excretion in 24-h Urine in Patients with Wilson Disease under Treatment of d-Penicillamine
    Lisu Huang
    Xiaodan Yu
    Jun Zhang
    Xiaoqing Liu
    Yongjun Zhang
    Xianting Jiao
    Xiaogang Yu
    Biological Trace Element Research, 2012, 146 : 154 - 159
  • [22] Metal Element Excretion in 24-h Urine in Patients with Wilson Disease under Treatment of d-Penicillamine
    Huang, Lisu
    Yu, Xiaodan
    Zhang, Jun
    Liu, Xiaoqing
    Zhang, Yongjun
    Jiao, Xianting
    Yu, Xiaogang
    BIOLOGICAL TRACE ELEMENT RESEARCH, 2012, 146 (02) : 154 - 159
  • [23] Urinary abnormalities in children and adolescents with Wilson disease before and during treatment with d-penicillamine
    Helmy, Heba
    Fahmy, Mona
    Aziz, Hanan Abdel
    Ghobrial, Carolyne
    Hameed, Nehal Abdel
    El-Karaksy, Hanaa
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2019, 34 (10) : 1824 - 1828
  • [24] Diagnostic value of 24 hr urinary copper excretion after penicillamine challenge in the adult Wilson's disease patients.
    Murru, A
    Curreli, NM
    Demelia, L
    HEPATOLOGY, 2004, 40 (04) : 576A - 576A
  • [25] Intrahepatic iron accumulation after D-penicillamine treatment in Wilson's disease
    Yano, M
    Yoshioka, K
    Kakumu, S
    Takikawa, T
    Hayashi, H
    HEPATOLOGY, 1996, 24 (04) : 290 - 290
  • [26] Wilson's disease before and after 5 years of treatment with D-penicillamine
    Zachoval, R
    Glaser, C
    JOURNAL OF HEPATOLOGY, 1998, 29 (03) : 489 - 489
  • [27] Nephrotic syndrome after treatment with D-penicillamine in a patient with Wilson's disease
    Kostadinova, Anna D.
    Mihaylov, Marian Y.
    Ivanova, Irena D.
    Robeva, Rayna T.
    REVISTA ROMANA DE MEDICINA DE LABORATOR, 2014, 22 (02): : 181 - 189
  • [28] D-penicillamine Induced Myasthenia Gravis in Wilson's Disease: A Case Report
    Thapa, Lekhjung
    Thapa, Monika
    Bhattarai, Suman
    Shrestha, Abhishek Man
    Sharma, Nooma
    Rai, Nilshan
    Pokharel, Merina
    Paudel, Raju
    JOURNAL OF NEPAL MEDICAL ASSOCIATION, 2022, 60 (251) : 644 - 647
  • [29] Manic Episode Induced by Discontinuance of D-Penicillamine Treatment in Wilson's Disease
    Kenar, Ayse Nur Inci
    Menteseoglu, Husnu
    KLINIK PSIKOFARMAKOLOJI BULTENI-BULLETIN OF CLINICAL PSYCHOPHARMACOLOGY, 2014, 24 (04): : 381 - 383
  • [30] D-penicillamine and plasmapheresis in acute liver failure secondary to Wilson's disease
    Fariña, ER
    Llurba, GT
    Quingles, XX
    Obradors, AL
    Alonso, JC
    Soler, JBG
    Núñez, CL
    REVISTA ESPANOLA DE ENFERMEDADES DIGESTIVAS, 2003, 95 (01) : 63 - 65